AdvertisementSupported byBreakingviewsBy ReutersThe embattled $40 billion pharmaceuticals company tried – but failed – to quell concerns about its convoluted dealings with distributors. Rob Cyran and Jeffrey Goldfarb discuss why.Advertisement